This is Living with CancerTM

At Pfizer Oncology, we believe it's our responsibility to help support and inspire those who have been affected by cancer. That's why Pfizer developed This Is Living With CancerTM, a program developed to support all people in their cancer journey.

Pfizer School of Science Mobile Experience

Pfizer School of Science Mobile Experience aims to spark curiosity and passion for STEM among future scientists through an interactive, hands-on, 'escape room' - like experience.

Global Health Fellows

At Pfizer, we're driven by our Purpose - to deliver breakthroughs that change patients' lives. Since 2003, Global Health Fellows has enabled colleagues to lend their skills to global health organizations working to strengthen health systems and close the health equity gap.

Clinical Trial Innovation: Putting the Patient First in Clinical Trial Design

Every day, scientists are developing potential new medicines and vaccines that could change lives. But to get medicines and vaccines to the patients who need them most, they must first undergo a clinical trial.

Closing the Mental Health Gap Among Rural Youth in the US

Young people in rural America can have the same hopes and dreams as other teenagers, but they can also face unique challenges. They often lack the resources found in more populated areas, making it harder to get help - or even know where to turn.

Connected. Active. Involved.

Welcome to the official website for retirees of Pfizer and its legacy organizations.

Pfizer News

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
August 28, 2024
Pfizer Launches PfizerForAllTM, a Digital Platform that Helps Simplify Access to Healthcare
August 27, 2024
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
August 12, 2024
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
July 30, 2024
European Commission Approves Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
July 25, 2024
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
July 24, 2024
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
July 11, 2024
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
July 09, 2024
Cyrus Taraporevala Elected to Pfizer's Board of Directors
July 01, 2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
Pfizer Declares Third-Quarter 2024 Dividend
June 26, 2024
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
June 18, 2024
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
June 16, 2024
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 14, 2024
Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
June 01, 2024
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
June 01, 2024
Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
May 31, 2024

Join the Pfizer Plus Community Corner

When you join the PfizerPlus.com community, you can get access to our special “member’s only” features including:

  • Member Only Content
  • Email Updates
  • PfizerPlus.com Community